Lv5
1020 积分 2023-04-17 加入
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
8天前
已关闭
Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
1个月前
已完结
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
2个月前
已完结
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
3个月前
已完结
Catumaxomab: First Approval
3个月前
已完结
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
3个月前
已关闭
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
3个月前
已完结
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
3个月前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
3个月前
已完结
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
3个月前
已完结
皖公网安备34019202002308
